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ABSTRACT 
CHARACTERIZATION OF THE FTFIHNF-4 SITES WITHIN THE 7ALPHA- AND 
THE 12ALPHA-HYDROXYLASE PROMOTERS INVOLVED IN THE BILE ACID- 
MEDIATED REGULATION OF THEIR TRANSCRIPTION 
By Preeti Pramanik, MS 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Dr Gregorio Gil 
Professor, Department of Biochemistry 
Bile acids regulate their own synthesis through a feedback regulatory mechanism 
of mainly two enzymes in the classic pathway, the 7a-hydroxylase and the 12a- 
hydroxylase. In the early 1990's it was shown that the regulatory responses of 7a-  
hydroxylase are mediated at the transcriptional level and since then many positive and 
negative transcription factors that mediate regulatory response have been identified. An 
important finding was that the transcription factors regulating the expression of 7a-  and 
12a-hydroxylase genes are nuclear receptors. 
. . . 
Vl l l  
One of the first nuclear receptors identified to play a role in the transcription of 
the 7a-hydroxylase gene was HNF-4 since then many nuclear receptors have been 
identified that are involved in regulating the 7a-  and 12a-hydroxylase genes. Among 
them the most important ones are FTF and HNF-4 which has been shown to play crucial 
roles in the transcription and regulation by bile acids. 
In this study we demonstrate the importance of FTF and HNF-4 independent of 
each other in the transcription and bile acid-mediated regulation of the 7aL and 12a- 
hydroxylase enzymes by creating promoter niutants that would either bind FTF or HNF- 
4. Once the binding studies were established we performed tissue culture experiments to 
confirm the promoter activity and bile acid-mediated regulation with the respective 
promoter mutant constructs. 
The data from this study shows that HNF-4 is important for 7a~hydroxylase 
promoter activity but is not required and importantly we show that HNF-4 is not a 
required for the bile acid-mediated regulation of the 7aLhydroxylase. We present data 
which suggests that FTF is absolutely required for the promoter activity and bile acid- 
mediated regulation of 7a~hydroxylase. With respect to the 12a~hydroxylase show that 
both FTF and HNF-4 are absolutely required for promoter activity. 
In this study we present evidence that since the bile acid responsive elements 
(BARE) are similar within both the 7a -  and 12a~hydroxylase promoters one can be 
exchanged for the other maintaining both activity and bile acid-mediated regulation. 
INTRODUCTION 
Cholesterol 
The cell membrane of most vertebrates, including humans, contains a single 
major sterol species known as cholesterol. It was first isolated from gallstones in 1784 
and ever since then it has been the fascination of scientists in every field of research. It is 
found in the external cellular membranes and in the layers that make up the myelin 
sheaths in the central and peripheral nervous systems. In the plasma membrane, the 
cholesterol molecules are intercalated between the phospholipid molecules to maintain 
membrane fluidity. Cholesterol is synthesized in eukaryotes from acetate precursors (1) 
and is the precursor of all other steroids in the body such as, corticosteroids, sex 
hormones, bile acids and vitamin D. Although cholesterol performs important functions 
in the mammalian cells, it has been observed that defects in cholesterol metabolism 
results in hypercholesterolemia, atherosclerosis and cholesterol gallstone disease. 
Therefore cholesterol homeostasis is very important. 
There are four metabolic pathways for regulating cholesterol homeostasis in the 
liver, first is the de novo synthesis of cholesterol from acetyl coenzyme A (1). Second is 
the uptake of serum cholesterol esters by low density lipoprotein (LDL) receptor 
mediated endocytosis (2). The third pathway in the maintenance of cholesterol 
homoeostasis involves catabolism to bile acids and the final pathway involves secretion 
of cholesterol into the bile. 
Of the total cholesterol catabolized approximately, 50% of cholesterol is 
catabolized to bile acids in the mammalian liver, 10% is used for synthesis of steroid 
hormones and the remaining 40% is removed together with bile acids and phospholipids 
via bilary excretion in stool (3). 
Bile Acid Biosynthesis 
Conversion of cholesterol to bile acids in the liver occurs via four different routes 
and more than 17 enzymes located in the endoplasmic reticulum, mitochondria, cytosol, 
and peroxisomes participate in bile acid synthesis (4). The most studied pathways are the 
"classic" (neutral) and the "alternative" (acidic) pathways (Fig. 1). The major end 
products of these pathways in humans, also known as primary bile acids are 
chenodeoxycholic acid, which has two hydroxyl groups at positions 3 a  and 7a ,  and 
cholic acid, which has three hydroxyl groups at positions 3a ,  7a ,  12a  and is thus more 
hydrophobic than chenodeoxycholic acid. The composition of bile acids in the bile 
affects the secretion of cholesterol and phospholipids from the liver as well as synthesis 
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of cholesterol and bile acids (3). 
The classic (neutral) bile acid biosynthetic pathway: 
The first step of this pathway, which is also the rate-limiting step, is catalyzed by 
the enzyme cholesterol 7a-hydroxylase (7a-hydroxylase) also known as CYP7A1 (4). 
Cholesterol 7a-hydroxylase is a microsomal cytochrome P450 isozyn~e expressed 
exclusively in the liver hepatocytes and converts cholesterol to 7a-hydroxycholesterol. 
In the next step, membrane bound microsomal 3 P-hydr~xy-C~~-steriod oxidoreductase 
oxidizes the 3P-hydroxyl group to 3-0x0 group and allows shifting of the double bond 
from position 5 to 4 in the steroid nucleus to form 7a-hydroxy-4-cholesten-3-one. This is 
a common precusssor for both cholic acid and chenodeoxycholic acid. Then 7a-hydroxy- 
4-cholesten-3-one is acted upon by the microsomal enzyme sterol 12a-hydroxylase (12a- 
hydroxylase) also known as CYP8B1, which is the specific enzyme for synthesis of 
cholic acid, to form 7a, 12a-dihydroxy-4-cholesten-3-one, a precursor of cholic acid. 
The cytosolic enzymes, 3-oxosteriod-5P-reductase and 3a-hydroxysteroid dehydrogenase 
catalyze the reduction of 7a,  12a-dihydroxy-4-cholesten-3-one into 5P-cholestane-3a, 
7a,  12a-triol. Alternatively, these two cytosolic enzymes, 3-oxosteriod-5P-reductase and 
3a-hydroxysteroid dehydrogenase, can also catalyze the reduction of 7a-hydroxy-4- 
cholesten-3-one into 5P-cholestane-3a, 7a,-diol, a precursor for chenodeoxycholic acid. 
The products of ring modification undergo oxidation and shortening of the sterol side 
chain in the subsequent steps, catalyzed by the enzyme sterol 27-hydroxylaselCYP27A1, 
to form oxidized bile acid intermediates. These intermediates exit in the mitochondria 
and undergo side chain cleavage by a variety of enzymes located in the peroxisome, 
mitochondria and endoplasmic reticulum, which results in the formation of cholic acid 
and chenodeoxycholic acid. Before secretion into the bile ducts, the primary bile acids 
undergo conjugation with either taurine or glycine to increase their hydrophilicity and 
solubility which makes them impermeable to cell membranes. 
The Alternative (acidic) Pathway: 
The initial step in this pathway, which is also the rate-limiting step is catalysed by 
sterol 27-hydroxylase, a mitochondria1 cytochrome P450 mono-oxygenase to form 27- 
hydroxysterol and 3P-hydroxy-5-cholestenoic acid (4). Sterol 27-hydroxysterol can be 
hydroxylated by microsomal oxysterol 7a-hydroxylase to 7a ,  27-dihydroxycholesterol. 
The product of this hydroxylation can undergo ring modification similar to those of the 
neutral pathway. The main end product of this pathway after oxidation cleavage of the 
side chain is chenodeoxycholic acid (5), although some studies suggest that cholic acid is 
also produced by the acidic pathway (6, 7). 
The newly formed primary bile acids are acted upon by anaerobic bacteria in the 
gut to convert them into secondary and tertiary bile acids (8). The pool of diversified bile 
acids in the lumen of the small intestine ensures complete emulsification of dietary lipids, 
fat-soluble vitamins and cholesterol. 
Decreased bile acid output is the major factor in the production of lithogenic bile, 
which leads to an abnormal ratio of cholesterol to bile acids and lecithin, a major risk 
factor for cholesterol gallstone formation. Since bile acids act as powerful detergents to 
facilitate the absorption of lipids, fat-soluble vitamins and cholesterol, proper control of 
bile acid synthesis is necessary and takes place mainly, at the transcriptional level (4). 
Regulation of Bile Acid Synthesis 
Accumulation of large quantities of hydrophobic bile acids in the hepatocytes is 
very toxic and therefore a tight control of bile acid synthesis and transport is necessary. 
This is brought about by negative feedback regulation of mainly two enzymes, 
cholesterol 7a-hydroxylase, which is the rate-limiting enzyme in the classic pathway and 
sterol 12a-hydroxylase, the specific enzyme for cholic acid synthesis (3,4). 
It was originally reported that the 7a-hydroxylase gene deficient mice die within 
few days of birth due to liver failure, vitamin deficiencies, and lipid malabsorption (9). 
Supplementing vitamins and bile acids to nursing mothers prevented death. These mice 
had 75% less bile acid pool and they reversed their pathologic phenotype (lo), and 
started producing bile acid via different pathways in which oxysterols rather than 
cholesterol serve as substrate. Recently, it was reported that the 7a-hydroxylase gene 
deficient mice survive and the survival of pups to adulthood is >65%, when they were fed 
normal rodent chow (1 1). The reason for these observations is unclear and all'of the 7a-  
hydroxylase gene deficient mice were hypercholesterolemic. 
The second important enzyme in the control of bile acid synthesis is sterol 12a- 
hydroxylase, a cytochrome P450 that catalyses the hydroxylation of the steroid nucleus at 
position 12. The specific activity, mRNA levels and the transcriptional activity of 12a- 
hydroxylase is inhibited by bile acids and stimulated by cholestyramine (7). Sterol 12a- 
hydroxylase is thus the specific enzyme for cholic acid synthesis and determines the ratio 
of cholic acid to chenodeoxycholic acid and thus the hydrophobicity of the circulating 
pool. The loss of 12a-hydroxylase activity eliminates synthesis of cholic acid (12) that 
leads to increased hydrophilicity of bile acids and hence less absorption of dietary 
cholesterol and higher hepatic cholesterol synthesis. Alteration in the rate of cholic acid 
and deoxycholic acid ratio has been implicated in the formation of cholesterol gallstones. 
Nuclear Receptors 
It has been recognized that the regulation of bile acid synthesis takes place, 
mostly at the transcriptional level and the transcription factors responsible for regulating 
the genes involved are nuclear receptors (4, 5). Many nuclear receptors are thought to 
play crucial roles in regulating the genes involved in bile acid synthesis and cholesterol 
metabolism. These nuclear receptors are present in the enterohepatic and peripheral 
tissues and are activated by micromolar concentrations of lipids, bile acids and steroids. 
The elements recognized by nuclear receptors involved in the transactivation of genes in 
bile acid synthesis have been identified as hexameric repeats of AGGTCA sequence with 
1,4, 5, nucleotide spacing. These are also known as DR-1, DR-4, and DR-5 (13). 
The structure of nuclear receptors consists of an activation function domain- I, a 
highly conserved DNA binding domain in the N-terminal region, followed by the Hinge 
region, a moderately conserved ligand-binding domain and activation function domain-2 
in the C-terminal region (14). There are two cysteine-coordinated zn2+ motifs in the 
DNA-binding domain which are involved in DNA binding and dimerization. The ligand- 
binding domain, in addition to determining ligand-specificity, contains a ligand-inducible 
transactivation function, and is also involved in the dimerization and interaction with 
coregulators (15). Upon ligand-binding the nuclear receptors undergo conformational 
change, release the corepressors and recruit the coactivators (1 6). 
Many nuclear receptors have no identified ligands for activation and are referred 
to as orphan nuclear receptors (14). Most of the ligands for nuclear receptors bind 
hydrophobic molecules to fit in the ligand- binding domain. The unique structure of the 
hydrophobic bile acids make them excellent candidates as endogenous ligands for orphan 
nuclear receptors (17). Many ligands for the nuclear receptors involved in the regulation 
of the above genes have recently been identified. Next we will review some of the key 
nuclear receptors involved in bile acid synthesis. 
Farnesiod X Receptor (FXR): FXR is expressed in the liver, gut, kidneys and the adrenal 
cortex and activates transcription in response to micromolar amounts of farnesol (18). 
FXR binds to an inverted repeat separated by one base pair (IRl), although it also binds 
weakly to DR4 and DR5 motifs (19). Several studies indicate that FXR is activated by 
bile acids and functions as bile acid receptor to repress 7a-hydroxylase transcription (20, 
2 1). 
Mice deficient in FXR express high levels of 7a-hydroxylase and 12a- 
hydroxylase mRNA, which results in increased synthesis of bile acids (22). These mice 
accumulate bile acid in the plasma due to decreased levels of ABCB 11, which transports 
bile acids from the hepatocytes into the bile (23). The FXR knockout mice are also 
hypertriglyceridemic due to decreased expression of apolipoprotein CII, which is 
required for triglyceride metabolism (24). 
Other target genes for FXR includes many ABC transporters for efflux of bile 
acids (23), and phospholipid transport protein for reverse cholesterol transport (25). 
Liver X Receptor (LXR): There are two LXR genes in mammals, LXRa and LXRP. It 
has been reported that LXRa plays a role in regulating cholesterol metabolism. Upon 
cholesterol accumulation in the hepatocytes, oxysterols activate LXRa, which 
heterodimerizes with RXR and binds to the DR-4 response element in the 7a-  
hydroxylase promoter (26). Another study reported that mice lacking LXRa, but having 
an intact LXRP, do not induce 7a-hydroxylase expression in response to cholesterol 
feeding (27). Mice lacking both LXRa and LXRP show severe phenotype (28). These 
studies established that LXRa is the cholesterol sensor responsible for feed-forward 
regulation of 7a-hydroxylase expression. However, it is important to note that although 
LXRa induces 7a-hydroxylase transcription in rats, the LXR element is either missing in 
species that do not respond to cholesterol (human and rabbit), or is present but 
nonfunctional in other nonresponding species (hamster) (29). 
LXR also plays a critical role in integrating the pathways of cholesterol synthesis 
and metabolism by regulating expression of sterol regulatory element binding protein-lc 
(SREBP-lc) gene (30). LXR stimulates the transcription of genes encoding cholesterol 
efflux proteins, ABCAI, ABCGS, and AGCG8 transporters and helps in the direct 
secretion of sterol from the liver (31) (32). There are numerous other genes involved in 
lipid metabolism that are targets of LXR (33), these include apolipoprotein E, ABCGI, 
phospholipid transfer protein (25), etc. 
a-Fetoprotein Transcription Factor (FTF): Also known as LRH- 1 (liver receptor 
homologue-1) and CYP7A promoter-binding factor (CPF) (34), or NR5A2 (35). It 
belongs to Fushi-tarazu factor-1 (Ftz-F1) family of nuclear receptors, and plays crucial 
roles in steriodogenesis, liver growth, endocrine development and differentiation. The 
Ftz-F1 P (NR5A2) gene encodes a-FTF and its homologs, rat FTF (36), human CPF (34), 
hepatitis B virus enhancer 1 factor (37), human FTF (38), mouse LRH (39). These 
variants differ in their N-terminal amino acid sequences and C-terminal truncation due to 
differential promoter usage and alternative mRNA splicing (37). Members of the Ftz-F1 
family bind as monomers to their response elements (29). 
FTF is expressed in the liver, intestine and the pancreas. It shares sequence 
identity with steroidogenic factor-1 (SF-I), a nuclear receptor which directs tissue- 
specific expression of genes involved in gonadal and adrenal steroidogenesis (40). The 
binding site of FTF has been identified in many genes which includes, 7a-hydroxylase 
(20), 12a-hydroxylase (41), SF-1 (42), SHP (43), HBV (44), HNF3P, HNF-4a ( 4 9 ,  etc. 
It has intrinsic transcriptional activity. Recently, phosphotidyl inositols phosphates have 
been identified as the ligand for FTF (46). 
It has been suggested that FTF functions as a competence factor for sterol 
regulation of mouse 7a-hydroxylase and human cholesterol ester transfer protein (CEPT) 
gene by LXR (47). FTF also induces multidrug-resistant protein-3 (Mrp-3) gene, 
involved in excretion of bile acids across basal lateral membrane into portal blood (48). 
There are a number of other genes like, HNF-3P (45), HNF-4a (45), HNF-la (45), 
adiponectin (ACDC) (49), ABST protein, ABCG5, and ABCG8 (50), steroidogenic acute 
regulatory protein (StAR) (5 I), scavenger receptor-BI (SR-BI), leutinizing hormone 
receptor (LHR) (52), 3P-HSD, 1 1 p-hydroxylase (53), 17,20-lyase (5 I), secretory 
phospholipase A2 (54), carboxyl ester lipase (55), etc, that are regulated by FTF binding. 
Hepatocyte Nuclear Factor-4a (HNF-4a): The most abundant orphan nuclear receptor 
in the liver binds to the DR-1 motif and regulates several liver specific and non-specific 
genes. It has constitutive activity and is able to transactivate gene with (56) or without 
ligand binding (57). HNF-4a binds to the DR-1 site in 7a-hydroxylase and 12a- 
hydroxylase, and also binds 27a-hydroxylase promoter. HNF-4a binding stimulates the 
7a-hydroxylase promoter (21). It has been reported that HNF-4a mediates bile acid 
repression of 12a-hydroxylase transcription (58). Phosphorylation of the DNA binding 
domain of HNF-4a by protein kinase A reduces its transactivation activity (59). 
Disruption of HNF-4a gene in mice is embroyonic lethal because HNF-4a is 
critical for early liver development and differentiation. Mice with induced hepatic 
deficiency of HNF-4 have markedly reduced expression of 7a-hydroxylase (60). The 
expression of oxysterol 7a-hydroxylase and 12a-hydroxylase genes is reduced to very 
low levels. 
There are a number of liver-specific genes involved in lipid metabolism, like 
ApoAI, ApoB and ApoCIII (61) whose expression is regulated by HNF-4a. HNF-4a 
binds as homodimer to the DR-1 motif and regulates their expression. HNF-4a also 
regulates transcription of a number of other genes including, glucokinase (62), 
pancreatic-P cell (63), HMG-CoA synthase (64), PPARa (65), PXR (66), guanylyl 
cyclase (67), macrophage stimulating protein (68), biliary glycoprotein (69), SREBP-lc 
(70), SREBP-2 (7 I), al-fetoprotein (72), etc. 
Short Heterodimer Partner (SHP): A unique nuclear receptor, which lacks the DNA 
binding domain but contains a receptor-interacting domain and a repressor domain (45). 
It inhibits transactivation activity of HNF-4a (73), FTF (74), RAR (75), CAR (76), 
PPAR (77), etc. SHP represses nuclear receptor activity by two mechanisms. First, it 
competes with other nuclear receptors for coactivators and second, SHP represses nuclear 
receptors directly by its repressor function located at the C-terminal (73). 
The promoter for the SHP gene contains an FXR response element composed of 
inverted repeats separated by single base pair (78). In addition to the FXR binding site in 
the SHP promoter, there is a functional FTF response element (46, 78). 
Regulation of Cholesterol 7a-Hydroxylase Expression 
Early studies showed that increasing the bile acid pool by bile acid feeding 
suppresses bile acid synthesis (79), whereas depletion of the bile acid pool by biliary 
diversion or bile acid sequestrant feeding increases bile acid biosynthesis (80). The 
molecular mechanisms responsible for regulation of cholesterol 7a-hydroxylase by bile 
acids and cholesterol have been the intense focus of many research groups in the past few 
years. 
Bile acids negatively regulate the transcription of 7a-hydroxylase gene in the 
classic pathway. It was reported that the rat cholesterol 7a-hydroxylase promoter 
contains two bile acid response elements, BARE I and BARE I1 between nucleotides 
-149 to +32 (3). Although, BARE I is an LXRa response element there is no evidence for 
its involvement in bile acid mediated regulation. The BARE I1 contains an overlapping 
HNF-4 and FTF binding sites from nucleotides -146 to -127 (Fig. 2) (20). HNF-4 binds 
to the DR-1 site and the direct repeat motif contains AG(G/T)TCA- like sequence. 
A number of mechanisms have been proposed for the suppression 7a-hydroxylase 
gene in response to bile acid accumulation and the majority of the mechanisms implicate 
nuclear receptors. It has been reported that bile acids bind to FXR (81-83). FXR then 
heterodimerizes with retinoid X receptor (RXR) and binds to an inverted repeat of 6 
nucleotides separated by one nucleotide (IR-I), and activates expression of SHP (78). 
SHP heterodimersizes with FTF, the major activator of 7a-hydroxylase promoter (34, 78, 
82), resulting in the repression of 7a-hydroxylase transcription. FTF binds to the GC- 
rich sequence TCAAGGCCG (84) in the 7a-hydroxylase promoter and is required for the 
transcriptional activation of the 7a-hydroxylase promoter in response to cholesterol 
accumulation(34, 78, 82). 
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This is consistent with FXR ' -  studies, which reports that FXR deficient mice 
accumulate high levels of 7a-hydroxylase and 12a-hydroxylase; this results in increased 
bile acid synthesis. Cholic acid feeding to these mice neither reduces 7a-hydroxylase 
and 12a-hydroxylase levels nor increases SHP levels. These findings suggest a 
mechanism that indirectly suppresses 7a-hydroxylase and 12a-hydroxylase gene 
transcription by bile acids through induction of SHP (85). 
Experiments in two independent lines of SHP knockout mice reveal only modest 
elevations in the levels of 7a-hydroxylase and 12a-hydroxylase gene expression (86), 
which is consistent with SHP repressing bile acid synthesis. However, 7a-hydroxylase 
and 12a-hydroxylase levels fall when these mice are fed bile acids but not when specific 
FXR agonist (GW4064) is administered to these mice. These results indicate that, 
additional SHP-independent pathways exit, which are capable of suppressing bile acid 
synthesis. 
Another mechanism that has recently been proposed for the down-regulation of 
7a-hydroxylase transcription is the involvement of c-Jun N-terminal kinase (JNK). In 
this mechanism, the JNK pathway is activated by bile acids, which in turn activates c-Jun 
resulting in higher SHP transcription (87). 
An alternate SHP-independent mechanism proposed for the suppression of 7a-  
hydroxylase transcription by bile acids is by inhibition of the transactivation potential of 
hepatocyte nuclear factor-4a (HNF-4) (88). 
The fourth mechanism, which also implicates HNF-4 for the regulation of 7a-  
hydroxylase transcription by bile acids, is that bile acids impair the recruitment of PPAR- 
y coactivatior- 1 a (PCG- 1 a )  and CAMP-responsive element- binding protein by HNF-4 
(88). 
Regulation of Sterol 12a-Hydroxylase Expression 
The other enzyme in the bile acid biosynthetic pathway also regulated by bile 
acids is 12a-hydroxylase (7), which also requires FTF for promoter activity (41). The rat 
12a-hydroxylase promoter contains a TATA box-like element, two consensus binding 
sites for HNF-3, two sterol regulatory elements (SREs) between nucleotides -233 to -206 
(36) and two overlapping sites (Fig. 2) for liver-specific nuclear receptor FTF between 
nucleotides -64 to +48 (41). 
The FTF sites within this promoter are absolutely required for bile acid-mediated 
regulation. Previous studies from our lab implicate the interaction between FTF and SHP 
in the bile acid mediated suppression of 12a-hydroxylase promoter. The distinctive 
domains required for the interaction of FTF and SHP has also been identified and studies 
suggest that FTF requires an intact SHP protein for the interaction between them in vivo. 
SHP prevents binding of FTF to its binding sites within the 12a-hydroxylase promoter, 
providing a mechanism of action for SHP-mediated suppression of 12a-hydroxylase 
transcription (74). 
Sterol 12a-hydroxylase gene knockout mice have increased chenodeoxycholic acid, 
murichlolic acid, bile acid synthesis and pool size, and cholesterol synthesis (12). The 
highly hydrophilic bile in these mice may derepress the cholesterol 7a-hydroxylase gene. 
It is also suggested that lack of cholic acid may decrease intestinal cholesterol absorption 
and hence stimulates de novo cholesterol synthesis in the liver (17). 
The two FTF sites in the 12a-hydroxylase promoter overlap with a direct repeat 
(DR-I), which is a functional PPAR binding site (89) between nucleotides -78 to -61 
(Fig. 2). This is similar to the 7a-hydroxylase promoter which also contains a DR-1 
element overlapping with the FTF binding site (Fig. 2) and it has been shown that HNF-4 
indeed does bind to and activate the 7a-hydroxylase promoter (90). 
The DR-1 is the binding site for HNF-4 among other nuclear receptors, and it has 
been hypothesized that HNF-4 is capable of competing with FTF for binding to the 
FTFIHNF-4 binding element in the 12a-hydroxylase promoter (93). The 7a-  and 12a- 
hydroxylase expression is higher in FTF " mice than in the wild type suggesting that FTF 
might be acting a negative factor of both. These mice not only have 3-7 fold higher 7a-  
and 12a- hydroxylase expression but their higher expression is reflected in a robust 
increase in total bile acids in the gallbladder with a higher ratio of cholic acid/n~urocholic 
acid ratio, reflecting higher 12a- hydroxylase expression in the FTF'" mice (91, 92). 
FTF overexpression experiments in mice suggest that FTF has two effects on 7a-  and 
12a- hydroxylase expression. First, it displaces HNF-4 from the FTFIHNF-4 site in 7a-  
and 12a- hydroxylase promoters and second it activates increased expression of SHP 
which suppresses FTF activity and hence transcription of 7a-  and 12a- hydroxylase (92). 
However, studies with short term overexpression of FTF using transgenic mice 
(TgF35) (91) carrying an FTF transgene controlled by the inducible MTI promoter 
showed 6-and 18-fold increase in mRNA levels of 7a-hydroxylase and SHP, 
respectively. This result pointed to an indirect mechanism for higher 7a-hydroxylase 
mRNA in the FTF"- mice and also supported the FTF activating effect on 7a-  
hydroxylase gene activity (91). This difference in result might be attributable to the 
technique used to overexpress FTF in the transgenic mice (TgF35). 
RATIONAL FOR THIS WORK 
From the studies referenced in the introduction, there is evidence for either FTF or 
HNF-4 to be involved in the bile acid mediated regulation of 7a-  and 12a-hydroxylase. 
A number of promoters have been identified which contain either FTF or HNF-4 site that 
bind FTF as monomer and HNF-4 as homodimers, but they are not regulated by bile 
acids. We hypothesize that the FTFI HNF-4 sites in the 7a-  and 12a-hydroxylase 
promoters are unique and that FTFIHNF-4 DNA elements that mediate bile acid 
regulation bind as FTFIHNF-4 heterodimer. 
Our lab has previously reported the importance of FTF binding for 7a-  hydroxylase 
and 12a-hydroxylase promoter activity and bile acid mediated regulation (82, 92). These 
studies were done by creating promoter mutants that would bind FTF but not HNF-4 in 
both the rat 7cx-hydroxylase and rat l2cx-hydroxylase promoter. However, a mutant that 
would bind HNF-4 but not FTF was not created. Such a mutant could help to elucidate 
whether HNF-4 is involved in the 7a-hydroxylase and 12a-hydroxylase promoter 
activity as well as bile acid-mediated regulation, since the DR-1 is the binding site for 
HNF-4 and it is a receptor know to interact with SHP (73). 
As discussed in the introduction, both 7a-hydroxylase and 12a-hydroxylase 
promoters' bile acid mediated regulatory elements are quite similar, as expected for two 
genes whose transcription is coordinately regulated by bile acids (7). In both promoters, 
the HNF-4 site overlaps the FTF site (92) and there are two functional FTF sites in the 
12a-hydroxylase promoter and apparently only one in the 7a-hydroxylase promoter (Fig. 
2) (34). We hypothesize that since the bile acid regulatory sites in both the 7a -  and 12a- 
hydroxylase promoters are similar one site can be exchanged for the other. 
Finally, in vivo overexpression of HNF-4 in mouse using adenovirus system will 
demonstrate whether HNF-4 is involved in the transcription of 7a-hydroxylase and 12a- 
hydroxylase genes. 
MATERIALS AND METHODS 
Materials 
Common laboratory chemicals were from Fisher, Sigma, Gibco & Bio-Rad. DNA 
cloning and sequencing reagents were from New England Biolabs, Boehringer 
Mamheim, US Biochemical Corp. and Gibco BRL. "P-ATP was purchased from ICN 
biomedical. Oligonucleotides were purchased from Integrated DNA Technologies. The 
luciferase promoter-less vector pGL3-Basic was purchased from Promega. Anti-FTF 
antibody was prepared against carboxy terminal peptide of the rabbit FTF sequence and 
was affinity-purified before use (in vitro studies). Anti-HNF-4 and anti-HDAC-1 
antibodies were obtained from Santa Cruz Biotechnology. Monoclonal anti-myc 
antibody was obtained from Sigma. 
Preparation of Chimeric 7a- and 12a-hydroxylase Promoter-Luciferase Reporter 
Constructs 
The pGL3-R7a-342 was prepared previously in our lab by PCR and contains -342 to 
+59 nucleotides, ligated to into the Smal site of pGL3-Basic vector. The three 7a -  
hydroxylase promoter constructs used for the experiments were made using a 
QuickChange site-directed mutagenesis kit (Stratagene) and the corresponding 
oligonucleotides shown in Table 1. 
QuickChange site-directed mutagenesis method: This procedure utilizes a template 
which is a double stranded DNA with an insert of interest and two oligonucleotide 
priniers that are complementary to the template and contains the desired mutation. The 
two oligonucleotide primers, opposite to the template are extended during temperature 
cycling by Pfu turbo DNA polymerase. The mutated plasmid generated was incubated 
with 1 p1 of Dpn I for 1 hr at 37°C. The Dpn 1 endonuclease is specific for methylated 
and hemimethylated DNA, and was used to digest the parent DNA and select the mutated 
plasmid. The plasmid DNA containing the desired mutation was transformed into DH5a 
cells, grown and sequenced to confirm the sequence of the mutant. 
The pGL3-R12a-865 was prepared in our lab by placing a 903-nucleotide Sacl- 
Sacl fragment containing nucleotides -865 to +37 into the Sacl site of pGL3-Basic 
vector from Promega. The 12a-hydroxylase promoter constructs, DR-1 mutant and FTF 
mutant used in the experiments were generated by using QuickChange site-directed 
mutagenesis kit (Stratagene), as described above. 
MUTAGESESlS OLIGONUCLEOTIDES 
- 
Mutant Mutagenesis Oligonucleotide 
7 a - H y d  DR-I M u t ( 1 )  CGC T C T  T C T  GAG A C T  ACA ACC TTA GTT CAA GGC CGG G 
7 a - H y d  DR-1 Mut ( 1 )  T T C  TGA GAC TAT t G A  a T T  AGT T C A  AGG CCG GGT A 
7 a - H y d  FTF Mut C T A  TGG ACT TAG T T C  AAC AAT GGG TAA TGC TAT TTT T T I  C 
I 2 a - H y d  DR-I M u t  G C T  A T T  TAC CAC GTC C g G  a c t  TAG TTC AAG GCC CAA TAT TAT G 
1 2 a - H y d  FTF Mut C T A  TGG ACT TAG T T C  A A c  a a t  GAA TAT TAT GGG CCG 
1 2 a i 7 a  CCA GAC T A t  G g a  C t t  a G T  t C A  AGG c G g  TGG GAA CAG CC 
1 2 a I 7 a  FTF Mut CCA GAC TAT GGA C T T  AGT TCA A c a  a t a  aGG GCC CAG CCA ACT TAT C 
OLIGONUCLEOTIDES USED FOREMSA 
Mutant EMSA Probes 
7a-Hyd M1-1 Mut ( 1 )  CrA GGA GAC TAc aac CTI A m  TCA AGG CCG GGT A 
7 u  -Hyd DR-1 Mut ( 2 )  TIC TGA GAC TAT tGA a m  AGT TCA AGG CCG GGT A 
7a-Hyd FTF Mut CTA GGA GAC TAT GGA CTT AGT TCA A c a  a t G  G G T  A 
l ? a - H y d D R - 1  Mut GCT ATT TAC CAC GTC CgG act TAG TTC AAG GCC CAA T A T  T A T  G 
12u-Hyd FTF Mut PGT CCA GAC TAT GGA CTI AGT TCA Aca atG FLAT ATT ATG GGC CGT TTG 
1 2 a i 7 a  CCA GAC T A t  G g a  C t t  a G T  t C A  AGG c G g  TGG GAA CAG CC 
1 2 a / 7 a  FTF Mut AGC TCA CAG ACT ATG GAC TTA GTT CAA caa t C G  T T  
Table 1- Sequences of mutagenesis oligonucleotides and EMSA probes used I in the erseriments. I 
The 12a-hydroxylase promoter construct 12a17a FTF mutant was generated by 
oligonucleotide-directed mutagenesis in M13. Mutagenesis oligonucleotide was 
phosphorylated using 5 mM ATP Tq polynucleotide kinase, annealed to M13 template 
and extended for 2 hrs at 14OC using the Klenow fragment of DNA polymerase I. The 
above reaction was diluted 1 : 10 and 3 p1 was used to transform TG- 1 competent cells. 
The transformation was screened for positive clones and 4 positive clones were grown 
overnight and the M13 DNA was isolated and sequenced. The DNA for a positive clone 
was resuspended in 20 p1 of water and extension reaction was carried out using 2.5 mM 
dNTP, oligonucleotide sequence - 5'-GAAACGACCCTCAACGTCCT-3', and the 
Klenow fragment of DNA polymerase I. The DNA was cut to yield the SacI-Sac1 
fragment (approximately 900bp). The fragment was purified by electro-elution 
technique. The SacI-Sac1 fragment was ligated to the pGL3 basic vector cut at the Sac1 
site. Ligation reaction was carried out overnight at 14OC. The pGL3-Sac-I ligated DNA 
was transformed into DH5a-cells. Colonies were picked, DNA isolated and sequenced 
to confirm mutation. 
Transformation of Recombinant Plasmids 
One hundred microliters of DH5a competent cells were transformed using the 
PCR product or ligation mixture with 0.8% polyethylene glycol (PEG), 10% of 50 mM 
KCL, 25 mM MgC12, and 15 mM CaC12 The mixture was incubated for 20 mins in ice 
followed by 10 mins at room temperature. One ml of Luria Broth (LB) was added to the 
above mixture and incubated for 45 mins at 37OC, followed by centrifugation at 5000 rpm 
for 5 mins. The supernatent was discarded and the pellet resuspended in 200 p1 of LB, the 
cells were then plated on LB containing 50 pglml ampicillin plates. The plates were 
incubated overnight in a 37°C incubator. 
Mini-preparation of Plasmid 
Three ml of LB containing 50 pglml of ampicillin was inoculated with a single 
bacterial colony and grown overnight in a 37°C shaker. After centrifugation for 5 mins 
the supernatent was discarded and the pellet was resuspended in lml of 10 mM NaCl and 
transferred into micro-centrifuge tube. Cells were pelleted at 10,000 rpm for 1 min and 
the supernatent was discarded. The pellet was resuspended in 150 pl of 25 mM Tris-HCl 
[pH 81 10 mM EDTA, 50 mM glucose, 4 mglnil lysozyme. Following 5 mins incubation 
at room temperatue 300 pl of 0.2 M NaOH and 1% SDS was added to the sample. After 
5 mins, 225 p1 of 5 M KAc was added and incubated for 5 mins then spun for 5 mins at 
10,000 rpm. The supernatent was transferred into another tube and the DNA was 
extracted with equal volume of phenollchloroform and ether to remove proteins followed 
by 3 M NaAc and 95% ethanol precipitation at -20°C for 30 mins. Sample was 
centrifuged for 10 mins at 10,000 rpm the pellet was dried and resuspended in 50 p1 of 
TE (10 mM Tris-HC1 [pH 7.61, 1 mM EDTA) containing 20 pglml of RNase. 
Appropriate enzyme digestion was done using 2 p1 of DNA, to confirm the presence and 
orientation of the fragment. 
Plasmid DNA Preparation 
Plasmid DNA was prepared as described by Sambrook et al, 1989. Single 
bacterial colony was inoculated into 1 L of LB containing 50 pglml of ampicillin and 
grown overnight in a 37 OC shaker. The culture was centrifuged at 4200 rpm for 10 mins 
and the supernatent was discarded. The pellet was resuspended in 9 ml of 50 niM Tris- 
HC1 (pH 7 3 ,  40 mM EDTA, 25% sucrose (wlv), lysozyme in a final concentration of 
0.3 mglml. Following 5 mins incubation at room temperature, 0.1M EDTA and 4 mg of 
RNase was added and incubated for 5 mins at room temperature. To the plasmid mixture 
was added 14.5 ml Triton solution, dropwise and centrifuged at 25,000 rprn for 45 mins 
to pellet the chromosomal DNA. 
The supematent was transferred into a 50 ml polypropylene tube and the weight 
of the supernatent was adjusted to 30.17 g with TE. To the sample tube was added 28.14 
g of ultra pure grade CsCl along with 4.5 ml of 10 mglml ethidium bromide and mixed 
thoroughly. The sample was transferred into polyallomer quick seal tube through a 60 ml 
syringe using 16 gauge needle. The tube was sealed according to manufacturer's 
instruction and centrifuged overnight at 45,000 rpm. 
Following centrifugation the tube was illuminated with long wave U.V. light to 
locate the plasmid band. The tube was first punctured on top for venting and then from 
side below to collect the lowest DNA band without disturbing any other bands containing 
chromosomal DNA, using a 10 ml syringe with a 16 gauge needle. Ethidium bromide 
was removed from the sample by extraction with equal volume of water-saturated butanol 
until ethidium bromide was completely eliminated. 
The sample was dialyzed against 4 L of TE containing 30 mM sodium acetate for 
2-3 hrs to remove CsC1. The plasmid DNA was extracted with phenol/chloroform as 
described above and appropriate digestions were done to confirm that the right plasmid 
was obtained. All the plasmids were confirmed by sequencing. 
Electrophoretic Mobility Shift Analysis and In vitro transcription/translation 
Binding reactions were done using 20 mM Tris-HCL (pH 8), 0.2 mM EDTA, 4% 
Ficoll, 1 pg of poly dl-dC, 4 p1 of protein, 1500-fold molar excess of irrelevent single 
stranded DNA, in a final volume of 20 pl. After 20 niins incubation on ice 350 fmol of 
indicated 3 2 ~  labelled DNA probe was added, followed by 20 mins incubation on ice. 
Samples were then loaded on a 4.5% polyacrylamide gel and subjected to electrophoresis 
at 180 volts, at 4OC. For supershift assays 1 pl of antibody was added followed by 20 
mins incubation on ice. The gels were dried and exposed to X-OMAT/ XAR 
autoradiography films from Kodak. In vitro proteins used were prepared using the TNT 
T7 coupled reticulocyte lysate system (Promega) according to manufacturer's protocol. 
Transient Transfection and Luciferase Asssays 
Primary hepatocytes were isolated from adult male Sprague-Dawley rats and 
prepared with collagenase perfusion-technique of Bissell and Guzelian. Hepatocytes (8.5 
x lo5) were plated onto 35 mm Falcon Primeria culture dishes. Prior to plating, cells were 
judged for >90% viability using trypan blue exclusion. Cells were incubated in 2 ml 
serum-free William's E medium supplemented with 1 pM thyroxine, 0.1 pM 
dexamethasone, 0.25 units/ml insulin, and 100 unitslml penicillin, glutamine in a 5% COz 
atmosphere at 37OC. Six hours after plating, hepatocytes were transfected with Lipofectin 
(Invitrogen) using 1 pg of total DNA, 100 ng of test plasmid, 2 ng of pCMV Gal (a 
plasmid containing human cytomegalovirus [CMV] promoter in front of the bacterial P- 
galactosidase gene) to normalize transfection efficiencies and 5 ng of pRSV-FXR. The 
DNA was removed 16 hrs after transfection and 50 pM taurocholic acid was added. 
Cells were harvested after 24 hrs and the luciferase and P-galctosidase assay was 
performed using a kit from Tropix (Bedford, MA) according to manufacture's protocol. 
All transfections were done in duplicate. Background activity (pGL3-Basic) was 
subtracted in each case. 
Human hepatocellular blastoma cells HepG-2 were obtained from American Type 
Culture Collection. HepG2 cells were transfected by the calcium phosphate method 
using 2 pg total DNA. HepG2 cells were transfected with 100 ng of test plasmid, 2 ng of 
pCMV-Gal to normalize transfection efficiencies. The DNA was removed 16 hrs after 
transfection and 50 pM chen~de~xycholic a id was added. The cells were harvested 48 
hours later and the luciferase and P-galactosidase assays were performed using Tropix 
(Bedford, MA) kit according to manufacture's protocol. 
Liver Nuclear Extracts Preparation 
Livers were obtained by harvesting mice (3 mice per group), rinsed in Ix ice cold 
SSC solution then placed in Thomas Tissue Grinder with 25 ml of homogenizing buffer 
(2 M sucrose, 25 mM KCL, 10 mM Hepes [pH 7.61, 1 mM EDTA, 0.15 mM sperrnine, 
0.5 mM spermidine, 1 mM DTT, 10% glycerol, 10 mM NaF, 0.5% milk). The livers 
were homogenized, filtered through a cheese cloth and centrifuged for 45 mins at 26,000 
rpm. The nuclei was resupended in 2 ml of nuclear lysis buffer (100 mM KCL, 10 mM 
Hepes [pH 7.61 0.1 mM EDTA, 3 mM MgC12, 10% glycerol, 5 mM NaF, 0.1 mM PMSF, 
1 mM DTT) and centrifuged at 9000 rpm for 10 mins. The nuclei were freezed in liquid 
nitrogen, resuspended in 250 p1 (per gram of liver) of nuclear lysis buffer and made 0.4 
M NaC1. The sample tubes were centrifuged for 1 hr at 45,000 rpm. The supernatant 
was dialyzed twice in dialysis buffer at 4OC and the samples were quantified for protein 
concentration by the Bradford method. 
Adenovirus Preparation and Propagation 
The adenovirus constructs used in this study was obtained through the Massey 
Cancer Center Shared Resource Facility of Virginia Commonwealth University. The 
pZeroTG1CMV-hHNF-4-myc-His needed to create the first adenovirus in the study was 
prepared as follows. A 1.4-Kb fragment of the hHNF-4 was obtained by PCR using the 
T7 promoter primer and the appropriate oligonucleotide complementary to the 3' end of 
the HNF-4 coding region. The HNF-4 cDNA was used as the template. After blunt 
ending and fragment purification the fragment was inserted in frame into 
pcDNA3.lImycHisA opened with EcoRV. An EcoRV fragment generated from hHNF- 
4-myc fragment was cloned into the EcoRV site of pZeroTG1CMV. The resulting 
pZeroTG1CMV-hHNF-4-myc plasmid was cotransfected with ClaI-linearized pTG/CMV 
(containing the entire Ad5d1324 genome) into Escherichia coli. Recombinant plasmids 
were transfected into human embryonic kidney 293 cells (American Type Culture 
Collection, Manassas, Va). Adenovirus DNA from the resulting plaques was further 
screened by analytical digestions for the presence of the insert. To purify the 
recombinant virus, the crude supernatant was carefully layered over a two-step CsCl 
gradient as described in (93). 
RNA Isolation and Quantification 
Total liver RNA was isolated by using the SV total RNA isolation kit (Promega) 
according to manufature's instructions. The 7a-hydroxylase, 12a-hydroxylase, LDL 
receptor, HMG CoA reductase, Apo-CIIII, Apo-AI, mRNA's were quantified by 
quantitative reverse transcription (Q-RT)-PCR using together the primers and probes 
shown in Table I1 and the Brilliant Q-RT-PCR Core Reagent kit (Startagene) probes with 
a DNA Engine Opticon2 (MJ Research Inc). All tlie values were normalized to the levels 
of actin mRNA, quantified also by Q-RT-PCR using TaqMan probes. 
Western Blot Analysis 
Three micrograms of liver nuclear protein was loaded onto 10% SDS- 
polyacrylamide gel, transferred onto nitrocellulose membrane, blocked for 1 -2hrs in 5% 
milk in TBST and incubated overnight at 4OC with anti-HNF-4 (1:1000), anti-myc 
(1 : 1000), and anti- HDAC- 1 (1 : 1000) antibodies. The membranes were washed 3 times in 
5% milk in TBST for 10 mins each, and incubated in appropriate secondary antibody 
(1:25,000) for 1 hr, after which the membranes were washed 3 times in 5% milk in TBST 
for 10 mins each. The membranes were then processed with Western Lightning 
Chemiluminescense Reagent Plus Kit (Perkins Elmer Life Sciences) according to 
manufacture's recommendations. - 
Oligo Gene GenBankTM No. Sequence 
m7a- T m7a-hydoxylase NM-007824 CAGGGCTCCTGATCATTTGAAATAAGCTCC 
m12a- T ml2a-hydoxyiase AF0903 19 TTAGGCCCTAGCATCACC AAGGATAGGCT 
mLDL-R-T mLDL-receptor NM-010700 TCTGCTCTTCACCAACCGCCACGA 
mAPO AT- T mAPO AI NM-009692 TCTGACTGCCCAGTGAGGTGCCCG 
mAPO CIII- T mAPO CIII NM-023 1 14 CGC TCCTCAC TGTGGCCC TCTTGG 
mp-actin- T mP-actin NM-007393 CCTGCGTCTGGACCTGGCTGGC 
I Table 2- Primers and Probes used in the Q-RT-PCR quantification of RNAs. I 
RESULTS 
In order to further characterize the FTF and HNF-4 sites in the 7a-  and 12a- 
hydroxylase we set out to create promoter mutants, that would bind only FTF or HNF-4 
and test their activity and regulation by bile acids. We first created mutants that should 
bind either FTF or HNF-4 and checked whether they indeed bind only FTF or HNF-4 
using in vitro made proteins. Once this was established, we moved to make the mutants 
in the chimeric 7a-  and 12a-hydroxylase promoter-luciferase reporter constructs and test 
them for activity and bile acid mediated regulation. 
Figure 3 shows a gel retardation assay using the 7a -  and 12a-hydroxylase 
FTFJHNF-4 site as probes using in vitro synthesized proteins. The FTF-, and HNF-4- 
DNA complexes migrate at approximately the same position with both probes, although 
the binding affinity of FTF and HNF-4 are different. We also used liver nuclear extracts 
with the 12a-hydroxylase probe in the same experiment to check whether nuclear 
extracts bind to this probe similarly to the in vitro made proteins. Interestingly, the 
binding and migration of FTF and HNF-4 using liver nuclear extracts with the 12a- 
hydroxylase probe is very different (Fig. 3, lane 5) ,  when compared to the in vitro made 
proteins where FTF is thought to bind as monomer and HNF-4 binds as dimer, suggesting 
that FTF and HNF-4 might be forming a heterodimer. 
7a-Hyd 12a-Hy d 




7a-Hyd: -154 T TCT GAG ACT ATG GAC TTA G 
-+ DR-1 
FTF FTF 
1 2 a a y d :  -80 CCA CGT CCA GCC TCA 
Fig.3 -FTF and HNF-4 bind to both the 7a- and 12a- hydroxylase promoters and the migra- 
tion of FTF and HNF-4 is different when liver nuclear extracts are used. 
A, gel shift experiment as described in "Materials and Methods" using in vitro made FTF, 
HNF-4 and liver nuclear extracts, and the indicated rat probes. The proteins used were 1 pl 
of FTF, 4p1 of HNF-4, and 3pg of liver nuclear extract. 
7a-Hydroxylase Promoter Mutants 
To analyze the role of DR-1 in the 7a-hydroxylase promoter we created two DR- 
1 mutants, 7a-Hyd DR-1 Mut 1 and Mut 2, the first DR-1 repeat was mutated leaving the 
FTF site virtually unmodified (Fig. 4 and 5, lower panel). To characterize the altered 
binding of HNF-4 and to check the binding of FTF to these two mutants, we performed 
supershift assays using the 7a-hydroxylase wild-type and mutant probes and in v i t~o  
made HNF-4, FTF, and GHR. Figure 4 shows that, as expected, the wild-type probe 
binds both HNF-4 and FTF but with different affinities. The HNF-4 and FTF bands were 
confirmed by supershifting the respective bands using anti-HNF-4 antibody and anti-FTF 
antibody. As expected the two DR-1 mutants do not bind HNF-4 at all but they differ in 
their ability to bind FTF. The reason for creating two DR-1 mutants was that the 7a-Hyd 
DR-1 Mut 1 probe binds FTF with lesser affinity as compared to the wild type probe 
(Fig. 4, lanes 2 and 9) whereas the 7a-Hyd DR-1 Mut 2 binds FTF similar to wild type or 
even better, (Fig. 5, lanes 2 and 9). 
In the third mutant, 7a-Hyd FTF we mutated four nucleotides within the FTF site 
leaving the DR-1 site unchanged (Fig. 6, lower panel). This mutant probe was not 
capable of binding to FTF but HNF-4 binding was similar to wild-type probe (Fig. 6, 
FTF + 
7a-Hydroxylase FTF 
Wild Type T TCT GAG ACT 
7a-Hydroxylase 
DR-1 Mut 1 T TCT GAG ACT Aca acC TTA GTT CAA GGC CGG GTA 
Fig.4 - Mutation in the DR-1 site completely abolishes HNF-4 binding and 
reduces binding of FTF in the 7a-hydroxylase promoter. 
Super shift experiment performed as described in "Materials and Methods' 
using the indicated probes and in vitro synthesized FTF or HNF-4 proteins 
or in vitro synthesized GHR as control. The lower panel shows the probes 
used. with the mutated nucleotides in lower case. 





Wild Type T TCT GAG ACT 
7a-Hydroxylase UK- I 
DR-1 Mut 2 T TCT GAG ACT A T t  GAa TTA GTT CAA GGC CGG GTA 
Fig.5 - Mutation in the DR-1 site completely abolishes HNF-4 binding and 
increases binding of ITF in the 7a-hydroxylase promoter. 
Super shift experiment performed as described in "Materials and Methods" 
using the indicated probes and in vitro synthesized FTF or HNF-4 proteins 
or in vitro synthesized GHR as control. The lower panel shows the probes 
used, with the mutated nucleotides in lower case. 
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C FTF HNF- 4 
7a-Hydroxylase 
Wild Type T TCT GAG ACT 
7a-Hydroxylase 
FTF Mut T TCT GAG ACT ATG GAC TTA GTT CAA caa ttGG GTA 
7a-Hyd FTF Mut 





Fig.6 - Mutation in the FTF site of the 7a-hydroxylase promoter completely abolishes FTF 
binding but has no effect on HNF-4 binding. 
Supershift experiment performed using the indicated probes and in vitro synthesized FTF or 
HNF-4 proteins or in vitro synthesized GHR as control. The lower panel shows the probes 
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lanes 5 and 12). As a negative control we used in vitro made GHR, which as expected, 
did not bind any of the probes. 
To study the promoter activity and bile acid mediated regulation, we tested the 
two DR-1 constructs, pGL3-7aIDR-1 Mut 1 and 2 and the pGL3-7aIFTF construct in 
tissue culture. We transfected them into primary hepatocytes that were incubated with or 
without 50 yM taurocholic acid. As expected, the two DR-1 constructs had promoter 
activity although very less as compared to the wild type construct. Both of these mutants 
were regulated by bile acids (Fig. 7). Most importantly, the pGL3-7aIFTF construct had 
minimal promoter activity but was not regulated by taurocholic acid, which support 
earlier studies (81) that suggests that FTF is required for the regulation of 7a-  
hydroxylase. 
12a-Hydroxylase Promoter Mutants 
In the introduction the importance of FTF binding for 12a-hydroxylase promoter 
activity and bile acid mediated regulation have been explained (41, 74). These studies 
were done by creating mutants that would bind FTF but not HNF-4 in the rat 12a- 
hydroxylase promoter. However, a mutant that would bind HNF-4 but not FTF was not 
PrornotcrAct~~ a) R w h t l o n  Blnd in g 
7a-Hydroxylase Wild Type 
1 ~ 4  - T C ~   OLD r r r  m r  4 
pCL3R7a-342 -1-17 ACT ATG GAC GTA -121 100 j j  i2 3 (3) +++ ++ 
7a-Hydmxylase DR-1 Mutants 
FT F 
pCL3R7a -342 DR-l mut I . . . . ca ac .. . -1 . . . 2 7 1 2  8 * 2  3.4(3) * - 
F T F  
p G L 3 R 7 o . 3 4 > D R . ] m u [ I  ... .t. ..a ... .+- --. 
7a-Hydroxylase FTF Mu tant 
+ --. . . ma . . . . . pCL3R7a-342FTF mu1 .. - - - - 
DR-I 
Fig.7 - Expression and bile acid-mediated regulation of 7a-hydroxylase promoterfluciferase 
DR-1 and FTF mutants in primary hepatocytes. 
Primary rat hepatocytes were transfected with the indicated constructs and treated with 
taurocholic acid as described in "Materials and Methods". The data were normalized to 
the activity produced by the wild type construct, pGL3 12a-342, in cells grown in the 
absence of taurocholic acid and represent the averages of n experiments * S.D. Lowercase 
refers to the promoter sections mutated as shown in the figure. 
created which could provide important insights whether HNF-4 is involved in the bile 
acid regulation of the 12a-hydroxylase promoter. 
To accomplish this, we used the 12a-hydroxylase FTF consensus mutant (74) as 
the template to create the 12a-hydroxylase FTF Mut 1 (Fig. 8, lower panel). To 
construct this mutant we first re-created the 7a-hydroxylase DR-lsite in the FTF 
consensus and then mutated the FTF site. This mutant probe does not bind FTF, as 
confirmed by performing supershift assay using anti-FTF antibody (Fig. 8, lanes 4 and 
11). HNF-4 binding is also less using this mutant probe (Fig. 8, lanes 5 and 12), probably 
due to mutations in the actual 12a-hydroxylase DR- 1 site. 
When tested in cell culture, this promoter construct pGL3 12a-865lFTF Mut 1 had 
no detectable activity which suggests that FTF is required for the 12a-hydroxylase 
promoter activity and HNF-4 binding alone is not sufficient for activity of the 12a- 
hydroxylase promoter. 
The BARE Site in the 12a-Hydroxylase Promoter can be Substituted by the BARE 
Site of the 7a-Hydroxylase Promoter 




WildType TAT TTA CCA CGT CCA GCC TCA 
12-HydFTFMut TAT TTA Cag acT atg GaC TtA Gtt CAA caa tgA Ata tta TG 
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Fig.8- Mutation in the FTF site of the 12a-hydroxylase promoter completely abolishes FTF binding 
and significantly reduces binding of HNF-4. A Supershift experiment performed using the 
indicated probes, antibodies, and in vitro synthesized FTF or HNF-4 proteins or in vitro synthe- 
sized GHR as control. The lower panel shows the probes used, with the mutated nucleotides in 
Inwer c a w  
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Fig.9.- Expression and bile acid-mediated regulation of 12a-hydroxylase promoter/luciferase 
DR-1 and FTF mutants in Hep G2 cells. 
Hep G2 cells were transfected with the indicated constructs and treated with chenodeoxycholic 
acid as described in "Materials and Methods". The data were norn~alized to the activity produced 
by the wild type construct, pGL312a-865, in cells grown in the absence of chenodeoxycholic 
acid and represent the averages of 17 experiments + S.D. Lowercase refers to the promoter 
sections mutated as shown in the figure. 
In the 12a-hydroxylase FTF Mut 1 shown above (Fig. 9) the HNF-4 site was placed 5' 
region of its wild type position in the 12a-hydroxylase promoter and thus, the results 
obtained might have been affected by this shifting. So the next approach was to create a 
promoter mutant that had the 7a-hydroxylase BARE exactly on the 12a-hydroxylase 
BARE. This was achieved by placing the 7a-hydroxylase FTFIHNF-4 site on the exact 
FTFIHNF-4 site of the 12a-hydroxylase promoter (Fig. 10, lower panel). This mutant 
should also allow us to study whether the 7a-hydroxylase and the 12a-hydroxylase 
BARE'S are exchangeable. To check and confirm the binding of FTF and HNF-4, 
supershift assay was performed with the respective antibodies using in vitro made FTF 
and HNF-4 with the wild-type and the 12a-Hydl7a Site Substitution probes. As 
expected, FTF and HNF-4 bound to the wild-type probe as well as to the 12a-Hyd17a 
Site Substitution probe. Although the HNF-4 binding to the 12a-HydJ7a Site 
Substitution probe was similar to the wild-type probe (Fig. 10, lanes 5 and 12), FTF 
binding was much more pronounced as compared to the 12a-Hyd wild type probe (Fig. 
10, lanes 2 and 9). 
Interestingly, when this promoter mutant was tested in tissue culture the promoter 
activity and the bile acid mediated regulation of this construct was similar to the 12a- 
hydroxylase wild- type promoter construct (Fig. 12). 
The next step in this study was to create a FTF mutant in the 12a-hydroxylase 
promoter by mutating the FTF site within the 12a-Hyd17a substitution probe (Fig. 11, 
lower panel). To check and confirm the binding of FTF and HNF-4 we performed a 
supershift assay using in vitro made GHR, FTF, and HNF-4. Figure 11 shows that FTF 
does not bind to this mutant probe whereas the HNF-4 binding was similar to the 12a- 
Hyd17a substitution probe. 
Tissue culture experiments performed using this mutant had no detectable activity 
(Fig. 12), which once again confirms that FTF is crucial for 12a-hydroxylase promoter 
activity. By creating this mutant we rule out that HNF-4 binding alone can mediate bile 
acid mediated regulation of l2a-hydroxylase atleast in tissue culture (81) (92). 
Fig. 10.- FTF and HNF-4 bath bind to the 12a-Hyd 7a Site Substitution probe, in which the 
BARE of the7a-h ydroxylase is placed on the BARE of the 12u-hydroxylase pro 
moter. Gel shift experiment performed using the indicated probes, antibodies, and in vi t ro  
synthesized FTF or HNF4 proteins or in vitro synthesized GHR as controL The shaded area 
shcnvs the site substitution. 
Fig. 1 1  - Mutation within the FTF site of the l2ci-Hyd 7 a  Site Sub completely 
abolishes FTF binding and significantly reduces binding of HNF-4 in 
the 12a-hydroxylase promoter. Gel shift experiment performed u sin g 
the indicated probes,antibodies, and in vitro synthesized FTF or HNF4 
proteins or in vitro synthesized GHR as control. 
Fig. 12- Expression and bile acid-mediated regulation of the 12a-hydroxylase promoterrlluciferase 
12a-Hyd 7a Site Sub and the 12eHyd 7a Site Sub FTF Mut in HepG2 cells. HepG2 cells 
were transfected with the indicated constructsand treated with chenodeoxycholic acid as described 
in "Materials and Methods". The data were normalized to the activity produced by the wild type 
construct, pGL3 12a-865, in cells grown in the absence of  chenodeoxycholic acid and representthe 
averages of n experiments * S.D. Lower case refers to the mutated promoter sections and the 
highlighted area shows the substitution. 
In vivo Overexpression Studies 
To demonstrate the involvement of HNF-4 in the transcription of key genes 
implicated in bile acid biosynthesis and regulation we carried out in vivo overexpression 
studies in mouse using adenovirus system. We used adenovirus carrying either HNF-4- 
myc or HNF-4 cDNA driven by the CMV promoter. In all the experiments, a control 
adenovirus containing the bacterial galactosidase coding sequence in front of the CMV 
promoter (Ad-Gal) was also injected. 
In the first experiment male mice were injected with either 5 x 101° or 3 ~ 1 0 ' ~  
viral particles of an adenovirus containing human HNF-4-myc cDNA in front of the 
CMV promoter (Ad-HNF-4-myc). Five days later these two sets of mice together with 
the control mice that had been injected with 5 x 10" viral particles of Ad-Gal were 
sacrificed and their livers harvested. The body weight of these animals did not change as 
a result of viral injections, and all the mice had similar weights between 22 and 25 g. 
Liver RNA was isolated and used to quantify 7a-, 12a-  hydroxylase, LDL receptor, 
HMG Co-A, Apo AI, and Apo CIII mRNAs by TaqMan Q-RT-PCR. Actin RNA was 
quantified and used to normalize RNA values. Interestingly, the 12a-hydroxylase mRNA 
was suppressed approximately 5- and 10-fold with the lower and higher injection of Ad- 
HNF-4-myc, respectively. Whereas the 7a-hydroxylase mRNA was minimally affected 
by the lower dose injection but there was no effect with the higher dose of the Ad-HNF- 
4-myc (Table 3 B). 
The adenovirus infection with Ad-HNF-4-myc described above produced 
considerable liver toxicity based on the plasma levels of liver marker enzymes such as 
alkaline phosphate, alanine aminotransferase and aspartate aminotransferase (Table 3 A). 
We performed a similar overexpression experiment with 4 x 10 l o  viral particles 
and the harvested the mice after 4 and 5 days. Quantification of the 12a-hydroxylase 
mRNA by TaqMan Q-RT-PCR showed approximately 10 fold suppression in the group 
of mice that were harvested after 4 days of injection. The 12a-hydroxylase mRNA 
quantification of the other group which was harvested after 5 days showed less 
suppression (- 5-fold) (Table 3 B). 
Condition ALK AL T AST 
I IL IL)  ( l L / I . l  (IC,LI 
p s a l  (5XI0l0) 
1231-7 701-24 8 6 . 5 2 3  
5  Days 
I - I N F ~ ( ~ X I O ' ~ )  
6 5 1 5 9 7  18265613 11075305 5  Days 
Table 3 .- HNF-4-myc over expression suppresses the 12a-hydroxyl ase 
gene in mice. 
A,  Clinical laboratory report to analyze the changes in total cho- 
les terol, and liver enzymes B, 12a-hydroxylase, 7a-hydroxylase , 
LDL receptor, HMG CoA reductase, Apo AI, and APO CIII 
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Fig. 13.- HNF-Cmyc overexpression suppresses the 12a-hydroxylase 
gene in mice. 
A, Clinical laboratory report to analyze the changes in total cho- 
lesterol, and liver enzymes B, 12a-hydroxylase mRNA quantifi - 
cation by RT-PCR as described in "Materials and Methods". C, 
Western blotting using liver nuclear extracts prepared from mice 
injected with gal (4 x 10'0) and HNF-4-myc adenovirus and (4 x 
101°) for4 and 5 days. 
However, under this condition also the liver marker enzymes were still affected by the 
virus infection (Fig. 13 A) and the marked increase in the liver enzymes might influence 
the mRNA level of 12a-hydroxylase gene. 
To analyze the amount of HNF-4 and myc in the liver we performed western 
blotting with liver nuclear extracts prepared from the livers of the harvested mice. In vitro 
HNF-4 was used as a positive control to identify the actual HNF-4 band, which suggests 
that these two bands might correspond to the abnormal processing of the overexpressed 
protein. The 4 days Ad-HNF-4-myc injected liver nuclear extract show two different 
bands with anti-HNF-4 antibody, and none of which correspond to the actual HNF-4 
band. The 5 days Ad-HNF-4-myc injected liver nuclear extract showed only one partial 
band not corresponding to the actual HNF-4 band (Fig. 13 C). The myc was much higher 
in the 4 days Ad-HNF-4-myc injected liver nuclear extract than in the 5 days Ad-HNF-4- 
myc injected liver nuclear extract (Fig. 13 C). 
In an attempt to avoid this toxicity, we performed another overexpression 
experiment but with Ad-HNF-4 without the myc tag. We injected two different amounts 
of Ad-HNF-4, 1 x 10" and 4 x 10l0, sacrificed the mice after 4 days and harvested the 
livers. Control Ad-Gal virus was injected to another set of mice in this group. Quite 
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Fig. 14.- HNF-4 overexpression suppresses 12a-hydroxylase gene in 
mice. 
A, Clinical laboratory report to analyze the changes in total cho- 
lesterol, triglycerides, HDL and liver enzymes B, 12a- 
hydroxylase mRNA quantification by RT-PCR as described in 
"Materials and Methods". C, Western blotting using liver nuclear 
extracts prepared from wild type mice, mice injected with gal (4 x 
10l0)  and HNF-4 adenovirus (1 x 10") and (4 x 10l0)  for 4 days. 
HNF-4 
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interestingly, there was suppression of 12a-hydroxylase mRNA with only the 'higher 
amount of the Ad-HNF-4 and with the lower amount of the Ad-HNF-4 there was an 
increase in the 12a-hydroxylase mRNA level. The level of 12a-hydroxylase mRNA in 
Ad-Gal was slightly increased. These overexpression study results with the AdHNF-4- 
myc and AdHNF-4, does suggest that HNF-4 might play an important role in regulating 
the 12a-hydroxylase gene transcription. 
The adenovirus infection with 4 x 10" produced limited liver toxicity, based on 
the liver marker enzymes but infection with 1 x 10" produced considerable toxicity 
(Fig.14 A). The suppression of 12a-hydroxylase mRNA might be attributed to the 
increased liver toxicity and hence more experiments needs to be done with lower 
amounts of virus to confirm the above results. 
The increase in HNF-4 protein was analyzed by performing a western blot using 
liver nuclear extracts prepared from adenovirus infected mice (Fig. 14 C). The blot shows 
that there is -10 fold increase in HNF-4 protein in the liver extracts of mice injected with 
1 x 10" viral particles as compared to the non-injected wild-type mice. 
A potential explanation for the observation made after HNF-4 overexpression is 
that the HNF-4 might be acting as a dominant negative HNF-4 mutant due either to the 
myc tag and/or to some potential mutation introduced in the overexpression constructs 
and hence the lower levels of mRNA of target genes. To characterize whether indeed 
that was the case we used the human apo CIII gene promoter which contains a well 
characterized HNF-4 binding site (57). We co-transfected this promoter with different 
amounts (Table 4) of either pZeroHNF-4-myc or pZeroHNF-4 expression plasmids. 
Table 4 shows that both expression plasmids caused a strong activation of the apo CIII 
promoter. The activation of apo CIII promoter was much more pronounced when the 
pZeroHNF-4-myc plasmid was used as compared to the pZeroHNF-4 plasmid (Table 4). 
These results, together with the high 1-evels of liver enzyme observed in the plasma (Table 
3 and Fig. 14) suggests that the suppression caused by overexpression of HNF-4 in mice 
is due to the inflammatory effect of the virus and not by the overexpressed genes acting 
as dominant negative mutants. 
Reporter Pbsillid Expmssiolr Plasmid Promoter Xcti\ it;v 
pLZS5-l ~ ~ ~ ~ 0 ~ 1 1 1  l( l0 
Table 4 -ApoCIII promoter activity is elevated by both HNF-4-myc and HNF-4. HepG2 cells 
were co-transfected with increasing amounts o f  expression vectors producing HNF-4- 
myc or  HNF-4 (amounts indicated in the table) together.with the wild-type ApoCIII 
promoter-luciferasereporter, pLZ854. Cells were harvested 36 hrs post transfection. 
m 
DISCUSSION 
Bile acids regulate their own synthesis through a feedback regulatory pathway. In 
the early 1990's it was shown that the regulatory responses of 7a-hydroxylase are 
mediated at the transcriptional level (4, 94) and since that time, the transcription factors 
that mediate positive and negative feedback regulation of bile acid synthesis have been 
identified. An important finding was that the transcription factors regulating the 
expression of 7a -  and 12a-hydroxylase genes are nuclear receptors (95). 
One of the first nuclear receptors identified to play a role in the transcription of 
the 7a-hydroxylase gene was HNF-4 (96), since then many nuclear receptors have been 
identified that are involved in regulating the 7a-hydroxylase gene. Aniong them the 
most important is FTF which has been shown not only to be required for the 
transcription of the 7a-hydroxylase gene (36) but also for its regulation by bile acids 
through dimerization with SHP (78). 
The second important enzyme in the neutral pathway is the 12a-hydroxylase and 
the expression of this gene is also regulated by bile acids and cholesterol (7). Our 
laboratory first showed that FTF is essential for 12a-hydroxylase transcription (41) and 
is also required for bile acid-mediated suppression by the FTFISHP pathway (74). 
In previous studies, to determine the roles of HNF-4 and FTF on the transcription 
and regulation of 7a-hydroxylase gene experiments were performed by creating promoter 
mutants by either mutating the DR-1 site or the FTF site. Results from these tissue culture 
studies indicated that FTF is essential for activity and bile acid-mediated regulation of the 
7a-hydroxylase promoter (81). However, in these studies binding of HNF-4 or FTF to 
the respective mutants was not shown and it was unclear whether FTF was able to bind to 
the DR-1 mutant and whether HNF-4 was able to bind to the FTF mutant. Similarly, to 
characterize the 12a-l~ydroxylase promoter studies were performed by creating promoter 
mutants within the 12a-hydroxylase promoter lacking the DR-1 site (74). These 
promoter mutants had no detectable activity suggesting that HNF-4 binding is crucial for 
the activity and perhaps regulation of 12a-hydroxylase expression (74). However, all the 
mutants that did not bind HNF-4 could not bind FTF either. No mutant could be created 
that would bind HNF-4 but not FTF in these studies, and thus the role of each of these 
factors could not be studied independent of each other. 
The first objective of this study was to further explore the role of both FTF and 
HNF-4 independent of each other in the transcription and bile acid-mediated regulation of 
the 7a-  and 12a-hydroxylase genes, by creating promoter mutants that would bind only 
HNF-4 or FTF. Secondly, due to the similarities between the BARE'S of the 7a-  and 
12a-hydroxylase, we wanted to study whether one site can be exchanged for the other. 
Finally, to investigate the role of HNF-4 in the 12a-hydroxylase expression in vivo we 
performed adenovirus overexpression studies in mice. 
In the experiments shown in this thesis, we were able to create 7a-hydroxylase 
promoter mutants that bound either HNF-4 or FTF only (Fig.4, 5, 6). Our studies show 
that within the 7a-hydroxylase promoter the HNF-4 site is important for activity 
(although not absolutely required) but is not required for bile acid-mediated regulation. 
The two DR-1 mutants in the 7a-hydroxylase promoter (Fig. 7) show lower activity 
(30%-40%) as compared to the wild type promoter, but most importantly these results 
indicate that the promoter is still regulated similar to the wild type promoter by bile acids. 
These results are in agreement with a recent publication that shows in vivo studies 
preformed in a conditional HNF-4 knockout mice in which the expression of 7a-  
hydroxylase mRNA is reduced in the dark cycle, indicating that HNF-4 controls 7a- 
hydroxylase gene expression (97). The FTF mutant created within the 7a-hydroxylase 
promoter binds HNF-4 similar to the wild type promoter (Fig. 6) but when tested in tissue 
culture this promoter mutant showed a dramatic reduction in promoter activity and no 
regulation by bile acids (Fig. 7), suggesting that FTF acts as a crucial factor for the 
promoter activity and bile acid-mediated regulation of 7a-hydroxylase transcription. In 
summary HNF-4 is important for 7a-hydroxylase expression but is not required, whereas 
FTF is essentially required. 
With respect to the 12a-hydroxylase promoter we were successful in creating a 
promoter mutant that would bind HNF-4 but not FTF within the 12a-hydroxylase 
promoter, called 12a-Hyd FTF Mut (Fig. 8), to analyze the role of HNF-4 in 12a- 
hydroxylase expression. We started by performing tissue culture experiments with the 
12a-Hyd-DR-1 MutIFTF consensus promoter construct which does not bind HNF-4 but 
binds FTF (74). Results from these experiments indicate that HNF-4 binding is crucial 
for 12a-hydroxylase promoter activity (Fig. 9) since this promoter showed no activity. 
Next we performed tissue experiments using the 12a-Hyd FTF Mut (this mutant binds 
HNF-4 but not FTF), and results show no activity of the 12a-hydroxylase promoter 
indicating that FTF is required for activity. Thus, in the 12a-hydroxylase gene, both FTF 
and HNF-4 are required for transcription (Fig. 9). 
Due to the overlapping of their binding sites (Fig. 2) FTF and HNF-4 could not 
bind simultaneously to the same 12a-hydroxylase promoter molecule if they bind as a 
monomer (FTF) and as a dimer (HNF-4), which is the current belief for other FTF- 
activated genes such as AFP (36) and HNF-4 activated genes such as apoCIII (61). 
However, the heterodimer FTFIHNF-4 could bind since the 5' FTF site (GCAAGGTCC) 
would be spaced by one nucleotide (A) from the HNF-4 3' repeat (AGGGCA) (Fig. 2). 
This arrangement for FTFIHNF-4 is similar to most nuclear receptor binding sites, which 
consists two repeats, either direct or reverse, spaced by 1 or 5 nucleotides depending on 
the specific receptor and gene (13). We have some evidence that the binding of FTF and 
HNF-4 to the 12a-hydroxylase promoter is different when liver nuclear extracts are used, 
than when we use in vitro made proteins (Fig. 3). When liver nuclear extracts were used 
the DNA-protein complexes migrates much slower than FTF monomer, which suggests 
that FTFIHNF-4 might be binding to the 12a-hydroxylase promoter as heterodimer. 
Since the BARE of 7a-and 12a-hydroxylase promoter are quite similar as 
expected for the two genes that are coordinately regulated by bile acids in this report we 
provide evidence that one site can be exchanged for the other. We substituted the BARE 
site in the 12a-hydroxylase promoter by the BARE site of the 7a-hydroxylase promoter 
(Fig. 10). Experiments performed in tissue culture using this promoter construct had very 
similar promoter acitivty and bile acid-mediated regulation as the wild type 12a- 
hydroxylase promoter construct, suggesting that one site can indeed be exchanged for the 
other (Fig. 12). We then created a mutant in the "hybrid" promoter which will eliminate 
the FTF site but still bind HNF-4 (Fig. 1 I), called 12a-Hydl7a Site Substitution FTF Mut 
and tested this mutant in tissue culture. The results from the 12a-Hydl7a Site 
Substitution FTF Mut, once again confirms that FTF is absolutely required for the 
promoter activity and bile acid-mediated regulation of 12a-hydroxylase (Fig. 12). 
To characterize the role of HNF-4 in vivo we performed overexpression studies in 
mice using an adenovirus system. The data from the HNF-4-myc and HNF-4 viral 
injection studies suggests that overexpression of HNF-4 might suppress 12a-hydroxylase 
mRNA but has minimal effect on 7a-hydroxylase mRNA (Table 3). A potential 
explanation for this result is that HNF-4 needs to be post-translationally modified (like 
phosphorylation) to be active. Overproduction of HNF-4 thus might be acting as a 
dominant negative factor since the over expressed HNF-4 might not be post- 
translationally modified by overwhelming the modification machinery. Another 
explanation is the high liver toxicity of the injected virus as evidenced by elevated liver 
enzymes, might have affected the results and hence more experiments need to be done to 
show which one of these two possibilities is correct, and then study whether HNF-4 is 
indeed involved in suppressing the 12a-hydroxylase mRNA. 
In summary, this study draws the following conclusions: 
1. HNF-4 is important for transcription of 7a-hydroxylase, although it is not 
required. 
2. HNF-4 does not appear to be required for the bile acid-mediated regulation of 7a-  
hydroxylase. 
3. Both FTF and HNF-4 are absolutely required for the expression of 12a- 
hydroxylase. 
4. The 7a-hydroxylase and the 12a-hydroxylase FTFIHNF-4 sites can be exchanged 
for each other, maintaining both activity and regulation. 
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